Florian Le Joubioux

Dr. Florian Le Joubioux

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
QHQuentin Haguet
Quentin Haguet
FJFlorian Le Joubioux
Florian Le Joubioux
VCVivien Chavanelle
Vivien Chavanelle
HGHugo Groult
Hugo Groult
NSNathan Schoonjans
Nathan Schoonjans
TMThierry Maugard
Thierry Maugard
Controlling post-prandial hyperglycemia and hyperlipidemia, particularly by regulating the activity of digestive enzymes, allows managing type 2 diabetes and obesity. The aim of this study was to assess the effects of TOTUM-63, a formulation of five plant extracts (Olea europaea L., Cynara scolymus L., Chrysanthellum indicum subsp. afroamericanum B.L.Turner, Vaccinium myrtillus L., and Piper nigrum L.), on enzymes involved in carbohydrate and lipid absorption. First, in vitro inhibition assays were performed by targeting three enzymes: α-glucosidase, α-amylase, and lipase. Then, kinetic studies and binding affinity determinations by fluorescence spectrum changes and microscale thermophoresis were performed. The in vitro assays showed that TOTUM-63 inhibited all three digestive enzymes, particularly α-glucosidase (IC50 of 13.1 µg/mL). Mechanistic studies on α-glucosidase inhibition by TOTUM-63 and molecular interaction experiments indicated a mixed (full) inhibition mechanism, and higher affinity for α-glucosidase than acarbose, the reference α-glucosidase inhibitor. Lastly, in vivo data using leptin receptor-deficient (db/db) mice, a model of obesity and type 2 diabetes, indicated that TOTUM-63 might prevent the increase in fasting glycemia and glycated hemoglobin (HbA1c) levels over time, compared with the untreated group. These results show that TOTUM-63 is a promising new approach for type 2 diabetes management via α-glucosidase inhibition.

7 May 2021 in Nutrients
Verified
Journal Article
Open access
PDF file
MDMarine Dupuit
Marine Dupuit
VCVivien Chavanelle
Vivien Chavanelle
Chassaing BenoitChassaing Benoit
Chassaing Benoit
FPFanny Perriere
Fanny Perriere
MEMonique Etienne
Monique Etienne
NBNathalie Boisseau
Nathalie Boisseau
Obesity and prediabetes are the two strongest risk factors of type 2 diabetes. It has been reported that TOTUM-63, a polyphenol-rich plant extract, has beneficial effects on body weight (BW) and insulin resistance in mice fed a high fat diet (HFD). The study aim was to determine whether high-intensity interval training (HIIT) and/or TOTUM-63 supplementation improved body composition and glycemic control and gut microbiota composition in a Western diet-induced obesity rat model. Wistar rats received a standard diet (CTRL; control; n = 12) or HFD (HFD; n = 48) for 16 weeks. Then, HFD rats were divided in four groups: HFD, HFD + TOTUM-63 (T63), HFD + HIIT (HIIT), and HFD + HIIT +T63 (HIIT + T63). Training was performed 4 days/week for 12 weeks. TOTUM-63 was included in diet composition (2%). The HIIT + T63 combination significantly limited BW gain, without any energy intake modulation, and improved glycemic control. BW variation was correlated with increased α-diversity of the colon mucosa microbiota in the HIIT + T63 group. Moreover, the relative abundance of Anaeroplasma, Christensenellaceae and Oscillospira was higher in the HIIT + T63 group. Altogether, these results suggest that the HIIT and TOTUM-63 combination could be proposed for the management of obesity and prediabetes.

3 May 2021 in American Journal of Physiology-Endocrinology and Metabolism
Verified
Journal Article
Open access
PDF file
VCVivien Chavanelle
Vivien Chavanelle
YOYolanda F. Otero
Yolanda F. Otero
FJFlorian Le Joubioux
Florian Le Joubioux
DRDoriane Ripoche
Doriane Ripoche
MBMaxime Bargetto
Maxime Bargetto
PSPascal Sirvent
Pascal Sirvent
Global prevalence of type 2 diabetes (T2D) is rising and may affect 700 million people by 2045. Totum-63 is a polyphenol-rich natural composition developed to reduce the risk of T2D. We first investigated the effects of Totum-63 supplementation in high-fat diet (HFD)-fed mice for up to 16 wk and thereafter assessed its safety and efficacy (2.5 g or 5 g per day) in 14 overweight men [mean age 51.5 yr, body mass index (BMI) 27.6 kg·m-2] for 4 wk. In HFD-fed mice, Totum-63 reduced body weight and fat mass gain, whereas lean mass was unchanged. Moreover, fecal energy excretion was higher in Totum-63-supplemented mice, suggesting a reduction of calorie absorption in the digestive tract. In the gut, metagenomic analyses of fecal microbiota revealed a partial restoration of HFD-induced microbial imbalance, as shown by principal coordinate analysis of microbiota composition. HFD-induced increase in HOMA-IR score was delayed in supplemented mice, and insulin response to an oral glucose tolerance test was significantly reduced, suggesting that Totum-63 may prevent HFD-related impairments in glucose homeostasis. Interestingly, these improvements could be linked to restored insulin signaling in subcutaneous adipose tissue and soleus muscle. In the liver, HFD-induced steatosis was reduced by 40% (as shown by triglyceride content). In the subsequent study in men, Totum-63 (5 g·day-1) improved glucose and insulin responses to a high-carbohydrate breakfast test (84% kcal carbohydrates). It was well tolerated, with no clinically significant adverse events reported. Collectively, these data suggest that Totum-63 could improve glucose homeostasis in both HFD-fed mice and overweight individuals, presumably through a multitargeted action on different metabolic organs. NEW & NOTEWORTHY Totum-63 is a novel polyphenol-rich natural composition developed to reduce the risk of T2D. Totum-63 showed beneficial effects on glucose homeostasis in HFD-fed mice, presumably through a multitargeted action on different metabolic organs. Totum-63 was well tolerated in humans and improved postprandial glucose and insulin responses to a high-carbohydrate breakfast test.

9 December 2023 in Nutrients
Verified
Journal Article
Open access
PDF file
Cédric LanghiCédric Langhi
Cédric Langhi
Marie VallierMarie Vallier
Marie Vallier
YOYolanda Otero
Yolanda Otero
MMMaheva Maura
Maheva Maura
FJFlorian Le Joubioux
Florian Le Joubioux
PSPascal Sirvent
Pascal Sirvent
Atherosclerotic cardiovascular disease is the leading cause of mortality worldwide, and hypercholesterolemia is a central risk factor for atherosclerosis. This study evaluated the effects of Totum-070, a plant-based polyphenol-rich supplement, in hamsters with high-fat diet (HFD)-induced dyslipidemia. The molecular mechanisms of action were explored using human Caco2 enterocytes. Totum-070 supplementation reduced the total cholesterol (−41%), non-HDL cholesterol (−47%), and triglycerides (−46%) in a dose-dependent manner, compared with HFD. HFD-induced hepatic steatosis was also significantly decreased by Totum-070, an effect associated with the reduction in various lipid and inflammatory gene expression. Upon challenging with olive oil gavage, the post-prandial triglyceride levels were strongly reduced. The sterol excretion in the feces was increased in the HFD-Totum-070 groups compared with the HFD group and associated with reduction of intestinal cholesterol absorption. These effects were confirmed in the Caco2 cells, where incubation with Totum-070 inhibited cholesterol uptake and apolipoprotein B secretion. Furthermore, a microbiota composition analysis revealed a strong effect of Totum-070 on the alpha and beta diversity of bacterial species and a significant decrease in the Firmicutes to Bacteroidetes ratio. Altogether, our findings indicate that Totum-070 lowers hypercholesterolemia by reducing intestinal cholesterol absorption, suggesting that its use as dietary supplement may be explored as a new preventive strategy for cardiovascular diseases.

11 April 2025 in Nutrients
Verified
Journal Article
Open access
PDF file
FWFabien Wauquier
Fabien Wauquier
DRDoriane Ripoche
Doriane Ripoche
BBBoutin-Wittrant Boutin-Wittrant
Boutin-Wittrant Boutin-Wittrant
YOYolanda F. Otero
Yolanda F. Otero
SKStephanie Krisa
Stephanie Krisa
yohann wittrantyohann wittrant
yohann wittrant
Background: TOTUM-854 is a patented plant extract blend characterized by its components that have previously been described for their potential health benefits in limiting hypertension onset. However, most of the literature data remain descriptive regarding the mode of action at the cellular level, especially in humans, and further investigations are required for optimized therapeutic strategies. Methods: We first demonstrated in an L-NAME mouse model that TOTUM-854 supports the prevention of hypertension in vitro and in vivo. Then, we designed an ex vivo clinical innovative approach considering the circulating metabolites produced by the digestive tract upon TOTUM-854 ingestion in humans. Human serum was collected in healthy volunteers before and after the acute intake of 3.71 g of TOTUM-854. The bioavailability of circulating metabolites was confirmed and characterized by UPLC-MS. Human serum containing TOTUM-854-derived metabolites was further processed for incubation with human endothelial cells (HUVECs), in the absence or presence of palmitate (200 µM). Results: HUVEC protection against lipotoxicity was characterized by (1) decreased ACE-1 activity (−32% p < 0.0001); (2) the inhibition of oxidative stress with decreased ROS (−12% observed by DCFDA and DHE fluorescent microscopy) and decreased Nox2 gene expression (−6.7 fold change vs. palmitate, p < 0.01); and (3) the inhibition of an inflammatory response, with a decrease in IL-1β release (−37% compared to palmitate, p < 0.001) and decreased MCP-1 and VCAM-1 gene expression (−93% p < 0.001 and −77% p < 0.001, respectively). Conclusions: Overall, this study provides insightful data regarding the protective role of TOTUM-854 in human endothelial cells. Using an innovative clinical ex vivo approach, our data support the role of TOTUM-854 circulating metabolites in vascular protection in humans.

14 June 2017 in OCL
Verified
Journal Article
Open access
PDF file
FJFlorian Le Joubioux
Florian Le Joubioux
NBNicolas Bridiau
Nicolas Bridiau
Marianne GraberMarianne Graber
Marianne Graber
TMThierry Maugard
Thierry Maugard
Ceramides are sphingolipid compounds that are very attractive as active components in both the pharmaceutical and the cosmetic industries. In this study, the synthesis of 1-O,3-N-diacyl 3-amino-1,2-propanediol-type pseudo-ceramides was developed at the semi-pilot scale, starting from a two-step continuous enzymatic process with immobilized Candida antarctica lipase B (Novozym® 435) in a packed-bed bioreactor, previously optimized at the laboratory scale. This process involved the selective N-acylation of 3-amino-1,2-propanediol (step 1), followed by the selective O-acylation of the N-acyl 3-amino-1,2-propanediol synthesized in the first step, with various fatty acids as acyl donors, to produce N,O-diacyl 3-amino-1,2-propanediol-type pseudo-ceramides (step 2). Under partially optimized operating conditions, high synthesis yields and production rates were obtained, within the ranges 76–92% and 3.7–4.6 g h−1 (step 1), or 23–36% and 1–1.4 g h−1 (step 2), respectively, depending on the fatty acids used as acyl donors. The overall synthesis yields varied from 20 to 33%: the best yield was obtained using palmitic acid and lauric acid as first and second acyl donors, respectively. Together with the high production rates also obtained with these acyl donors, this confirms that this two-step process has great potential for the production of differently functionalized 1-O,3-N-diacyl 3-amino-1,2-propanediol-type pseudo-ceramides on an industrial scale. Les céramides sont des sphingolipides, composés actifs d'intérêt majeur pour les industries pharmaceutique et cosmétique. Lors de la présente étude, la synthèse de pseudo-céramides de type 1-O,3-N-diacyl 3-amino-1,2-propanediol a été développée à l'échelle semi-pilote, à partir d'un procédé enzymatique continu en deux étapes impliquant la lipase B de Candida antarctica (Novozym® 435) utilisée au sein d'un bioréacteur à lit fixe, préalablement optimisé à l'échelle du laboratoire. Ce procédé conjuguait la N-acylation sélective du 3-amino-1,2-propanediol (étape 1) suivie de la O-acylation sélective du N-acyl 3-amino-1,2-propanediol synthétisé lors de la première étape, impliquant différents acides gras comme donneurs d'acyles, pour produire des pseudo-ceramides de type N,O-diacyl 3-amino-1,2-propanediol (étape 2). Sous conditions opératoires partiellement optimisées, de hauts rendements de synthèse et vitesses de production ont été obtenus, respectivement de l'ordre de 76–92 % et 3,7–4,6 g h−1 (étape 1), ou 23–36 % et 1–1,4 g h−1 (étape 2), en fonction des acides gras utilisés comme donneurs d'acyles. Les rendements de synthèse globaux ont évolué de 20 à 33 % : le meilleur rendement a été obtenu en utilisant respectivement l'acide palmitique et l'acide laurique comme premier et second donneurs d'acyles. Associé à la vitesse de production importante également atteinte avec ces donneurs d'acyles, cela confirme que ce procédé en deux étapes présente un potentiel élevé pour la production à l'échelle industrielle de pseudo-céramides de type 1-O,3-N-diacyl 3-amino-1,2-propanediol diversement fonctionnalisés.